Allogene Therapeutics, Inc. — fact timeline

Allogene Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-18 meeting.

“Proposal 5. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 282,022,884 503,156 198,378 0”

Allogene Therapeutics, Inc. shareholders approved Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares at the 2026-06-18 meeting.

“Proposal 4. Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares The Company’s stockholders approved an amendment (the "Amendment") to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 221,767,995 6,535,254 122,159 54,299,010”

Allogene Therapeutics, Inc. shareholders approved Approval, on an Advisory Basis, Say-On-Pay Vote Frequency at the 2026-06-18 meeting.

“Proposal 3. Approval, on an Advisory Basis, Say-On-Pay Vote Frequency The Company’s stockholders approved, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. The final voting results are as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 224,054,368 228,313 757,992 3,384,735 54,299,010”

Allogene Therapeutics, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers at the 2026-06-18 meeting.

“Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 213,098,167 11,951,256 3,375,985 54,299,010”

Allogene Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Deborah Messemer 202,325,767 26,099,641 54,299,010 Vicki Sato, Ph.D. 202,326,299 26,099,109 54,299,010 Owen Witte, M.D. 189,310,484 39,114,924 54,299,010”

Zachary Roberts changed role as Chief Medical Officer (interim) at Allogene Therapeutics, Inc..

“Dr. Roberts currently serves as the Company’s Executive Vice President, Research and Development, and Chief Medical Officer and will continue serving as the Company’s Chief Medical Officer on an interim basis following the Effective Date.”

Zachary Roberts was appointed as Class I director at Allogene Therapeutics, Inc..

“Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director”

David Chang was appointed as non-employee director at Allogene Therapeutics, Inc..

“Dr. Chang will remain on the Board and will become a non-employee director commencing on the Effective Date”

David Chang resigned as President and Chief Executive Officer at Allogene Therapeutics, Inc..

“Dr. Chang’s last day of service in these positions will be June 30, 2026.”

Zachary Roberts was appointed as President and Chief Executive Officer at Allogene Therapeutics, Inc..

“the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.”

Allogene Therapeutics, Inc. entered into Second Amended and Restated Shareholders’ Agreement with Overland Therapeutics Inc. and HH BioPharma Holdings Ltd. valued at Restructuring of Allogene’s equity ownership and governance rights with respect to Overland (effective 2026-05-12).

“The Shareholders Agreement amends and restates the prior shareholders’ agreement and reflects a restructuring of Allogene’s equity ownership and governance rights with respect to Overland.”

Allogene Therapeutics, Inc. terminated Exclusive License Agreement, dated December 14, 2020, as amended on May 24, 2024 with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc. valued at No termination payments were made; upfront payment $40.0 million and non-cash consideration of $79.0 (effective 2026-05-12).

“The Termination Agreement provides that the License Agreement is terminated in its entirety, subject to certain customary survival provisions.”

Allogene Therapeutics, Inc. reported financial results for for the quarter ended March 31, 2026.

“Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2026 in the press release attached hereto as Exhibit 99.1”

Allogene Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $190.9 million, EPS $0.87 per share.

“For the full year of 2025, net loss was $190.9 million, or $0.87 per share, including non-cash stock-based compensation expense of $37.6 million and non-cash impairment of long-lived asset expense of $2.4 million.”

Allogene Therapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income $38.8 million, EPS $0.17 per share.

“Net loss for the fourth quarter of 2025 was $38.8 million, or $0.17 per share, including non-cash stock-based compensation expense of $8.1 million.”

Timothy Moore departed as other_named_officer at Allogene Therapeutics, Inc..

“On January 23, 2025, Allogene Therapeutics, Inc. (the “Company”) and Timothy Moore agreed that Mr. Moore would be leaving his employment with the Company on February 28, 2025.”

Allogene Therapeutics, Inc.: Amendments to the Company's Code of Business Conduct and Ethics to update and clarify standards, including insider trading policy, antitrust compliance, conflicts of interest, outside business opportunities, record integrity, fair dealing, gifts, asset protection, spokesperson authority, data privac (effective 2024-10-03).

“On October 3, 2024, the Audit Committee of the Board of Directors of Allogene Therapeutics, Inc. (the “Company”) adopted and approved certain amendments to the Company’s Code of Business Conduct and Ethics (the “Code”) that applies to all directors, officers, employees and certain consultants and contractors of the Company (“Covered Persons”).”

Geoffrey Parker changed role as principal accounting officer at Allogene Therapeutics, Inc..

“Mr. Parker continues to serve as the Company’s Chief Financial Officer and principal financial officer.”

Annie Yoshiyama was appointed as principal accounting officer at Allogene Therapeutics, Inc..

“appointed Annie Yoshiyama, the Company’s current Senior Vice President and Corporate Controller, as the Company’s principal accounting officer, effective immediately, replacing Geoffrey Parker in such capacity.”

Allogene Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

“Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1”

Allogene Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2023.

“On March 14, 2024, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.”

Allogene Therapeutics, Inc. reported that prior financial statements should not be relied upon.

“on February 14, 2024, the Company’s Audit Committee of the Board of Directors of the Company (the “Audit Committee”) determined, based on management’s recommendation and after consultation with Ernst & Young LLP, the Company’s independent registered public accounting firm, that the Seed Preferred Shares should have been initially measured at fair value, and the accounting for the Seed Preferred Shares should be restated. As a result, the Audit Committee also determined that the Company’s financial statements for the years ended December 31, 2020, 2021 and 2022, and in each of the Company’s quarterly reports on Form 10-Q filed with the SEC in 2021, 2022 and 2023 (collectively, the “Restatement Periods”), should no longer be relied upon”

Allogene Therapeutics, Inc. amended Amended and Restated Collaboration and License Agreement with Notch Therapeutics, Inc. valued at Amended and restated collaboration and license agreement; company relinquished exclusive rights to o (effective 2024-01-25).

“On January 25, 2024, Allogene Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Collaboration and License Agreement (the “Amended Agreement”) with Notch Therapeutics, Inc. (“Notch”).”

Allogene Therapeutics, Inc. announced a restructuring with charges of charges of approximately $5.0 million to $5.5 million for severance payments and employee benefits affecting financial.

“The Company estimates that it will incur charges of approximately $5.0 million to $5.5 million for severance payments and employee benefits, primarily in the first quarter of 2024.”

Allogene Therapeutics, Inc. announced a restructuring with charges of reduction in the Company’s workforce of approximately 22% of the Company’s employees in connection with the Company’s pipeline prioritization and clinical devel affecting workforce (approximately 22% of the Company’s employees).

“On January 4, 2024, the Company’s Board of Directors approved a reduction in the Company’s workforce of approximately 22% of the Company’s employees in connection with the Company’s pipeline prioritization and clinical development strategy.”

Allogene Therapeutics, Inc. entered into Strategic Collaboration Agreement with Foresight Diagnostics, Inc. (effective 2024-01-03).

“On January 3, 2024, Allogene Therapeutics, Inc. (the “Company”) entered into a Strategic Collaboration Agreement (the “Agreement”) with Foresight Diagnostics, Inc. (“Foresight”).”

Allogene Therapeutics, Inc. reported financial results for for the quarter ended September 30, 2023.

“Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.”

Jack Chen changed role as Interim Principal Accounting Officer at Allogene Therapeutics, Inc..

“replacing David M. Chang, M.D., Ph.D. and Jack Chen in their capacities as the Company’s interim principal financial officer and interim principal accounting officer, respectively.”

David M. Chang changed role as Interim Principal Financial Officer at Allogene Therapeutics, Inc..

“replacing David M. Chang, M.D., Ph.D. and Jack Chen in their capacities as the Company’s interim principal financial officer and interim principal accounting officer, respectively.”

Geoffrey Parker was appointed as Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Allogene Therapeutics, Inc..

“appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023”

Geoffrey Parker was appointed as Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Allogene Therapeutics, Inc..

“The Board of Directors of Allogene Therapeutics, Inc. (the “Company”) appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023.”

Allogene Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.

“On August 2, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.”

Allogene Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-13 meeting.

“Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 120,675,447 36,870 9,115 0”

Allogene Therapeutics, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers at the 2023-06-13 meeting.

“Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 73,082,912 31,751,974 1,939,920 13,946,626”

Allogene Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-13 meeting.

“Proposal 1. Election of Directors The Company’s stockholders elected the four persons listed below as Class II Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Deborah Messemer 90,975,252 15,799,554 13,946,626 Vicki Sato, Ph.D. 105,736,345 1,038,461 13,946,626 Todd Sisitsky 86,678,264 20,096,542 13,946,626 Owen Witte, M.D. 88,677,813 18,096,993 13,946,626”

Eric Schmidt resigned as Chief Financial Officer at Allogene Therapeutics, Inc..

“On June 9, 2023, Eric Schmidt, Ph.D., the Chief Financial Officer, principal financial officer and principal accounting officer of Allogene Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign, effective at the close of business on August 2, 2023, to spend more time with his family.”

Allogene Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.

“On May 3, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.”

Tim Moore was appointed as Chief Technical Officer at Allogene Therapeutics, Inc..

“On April 19, 2023, the Company’s Board of Directors appointed Tim Moore to serve as Chief Technical Officer, effective April 24, 2023.”

Alison Moore resigned as Chief Technical Officer at Allogene Therapeutics, Inc..

“On April 18, 2023, Alison Moore, the Chief Technical Officer of Allogene Therapeutics, Inc. (the “Company”), notified the Company of her decision to resign effective April 28, 2023 to pursue other opportunities.”

Allogene Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2022.

“On February 28, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.”

Rafael G. Amado resigned as Executive Vice President of Research and Development at Allogene Therapeutics, Inc..

“On December 27, 2022, Rafael G. Amado, M.D., the Executive Vice President of Research and Development of Allogene Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign, effective December 30, 2022, to pursue another opportunity.”

Allogene Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $83.1 million, EPS $0.58 per share.

“Net loss for the third quarter of 2022 was $83.1 million, or $0.58 per share”

Stephen Mayo was appointed as Director at Allogene Therapeutics, Inc..

“On July 8, 2022, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased the authorized number of directors on the Board from eleven to twelve, and appointed Stephen Mayo, Ph.D. as a Class III director of the Company to fill the newly created vacancy, effective immediately, with a term of office expiring at the Company’s 2024 annual meeting of stockholders.”

Elizabeth Barrett was appointed as Class I director at Allogene Therapeutics, Inc..

“appointed Elizabeth Barrett as a Class I director of the Company to fill one of the newly created vacancies, effective immediately”